Modulating T Cell Binding to Mitigate CRS Risk

Cytokine release syndrome (CRS) is a most frequent serious adverse effects of immuno-therapy in the systemic circulation

CrossBody technology offers exceptional flexibility in efficiently modulating both tumor and T cell binding (not affinity maturation) while retaining potent efficacy in tumor cells